ArticleActa dermato-venereologica2020
Early-stage Mycosis Fungoides: Epidemiology and Prognosis.
Article in Acta dermato-venereologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Diagnostic delay in mycosis fungoides: Insights from China's first multicentre registry of 305 patients.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Mycosis Fungoides With Large Cell Lymphoma Transformation: A Report of a Rare Case.The American journal of case reports · 2026Article
- When Cellulitis Is Not Cellulitis: A Case of Suspected Mycosis Fungoides With Nondiagnostic Biopsies.Cureus · 2026Article
- Mycosis fungoides and Sézary syndrome.British journal of haematology · 2026Review
- Sonographic Assessment of Peripheral Lymph Nodes In Early-Stage Mycosis Fungoides: Diagnostic Value And Prognostic Implications.Dermatology practical & conceptual · 2026Article
- The dual burden of a rare cancer: psychosocial impact of disease symptoms and unmet care needs in cutaneous T-cell lymphoma.Frontiers in psychology · 2026Article
- Dermatoscopic Patterns in Mycosis Fungoides: Observations from a Case-Series Retrospective Analysis and a Review of the Literature.Diagnostics (Basel, Switzerland) · 2025Article
- Overall and Cause-Specific Mortality Among Patients With Cutaneous T-Cell Lymphoma in the United States.EJHaem · 2025Article
- Identification of subgroups of early-stage mycosis fungoides patients with increased itch and impaired quality of life.Frontiers in oncology · 2025Article
- Spanning 17 Years: Diagnostic Evolution from Lichen Planus Pigmentosus to Hyperpigmented Mycosis Fungoides.Clinical, cosmetic and investigational dermatology · 2025Article
- Perspectives on the Mature T-Cell Lymphomas in the Middle East: A Comprehensive Review of the Present Status.Cancers · 2024Review
- Article
- Importance of the C-Reactive Protein to Albumin Ratio in the Diagnosis and Prognosis of Mycosis Fungoides.Dermatology practical & conceptual · 2024Article
- GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.Oncotarget · 2024Article
- Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides.Scientific reports · 2024Article
- Article
- Article
- Case Report: Mycosis fungoides as an exclusive manifestation of common variable immunodeficiency in a family with aFrontiers in oncology · 2023Article
- Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion.American journal of clinical dermatology · 2023Review
- Cutaneous pseudolymphomatous drug eruption secondary to supplemental flaxseed oil.JAAD case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients with mycosis fungoides are diagnosed with early-stage disease. However, prevalence of early-stage disease is unknown, and evidence of its burden is scarce. The aim of this study is to estimate the prevalence of early-stage mycosis fungoides, how long patients live with early-stage disease and to characterise these patients. Data were obtained from 4 key publications and from US cancer registries (Surveillance, Epidemiology and End Results Program; SEER). The derived incidence of early-stage mycosis fungoides was 0.26/100,000 (UK), 0.29/100,000 (US) and 0.38/100,000 (US-SEER) and the prevalence was 4.8/100,000 (UK), 5.2/100,000 (US) and 6.6/100,000 (US-SEER). Early-stage disease may last for 18 years. From SEER registries, 3,132 were diagnosed at early stage (mostly stage IA). Median age at diagnosis was 58 years. Compared with stage IA, the relative risk of death was 1.3 for stage IB and 3.5 for stage IIA. We confirm the rarity of early-stage mycosis fungoides, a differential prognosis and the potential for elevated burden of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.